Skip to main content
SpringerLink
Log in

Aripiprazole

OPC 14597

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Toru M, Miura S, Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology 1994 May; 10 Suppl. Pt 1: 122

    Google Scholar 

  2. Toru M, Miura S. Late phase II study of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Eur Neuropsychopharmacol 1996 Jun; 6 Suppl. 3: 18

    Article  Google Scholar 

  3. Inoue A, Miki S, Seto M, et al. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997 Feb 19; 321: 105–11

    Article  PubMed  Google Scholar 

  4. Uwahodo Y, Kikuchi T, Tottori K, et al. Pharmacological profile of OPC-14597, a novel anti-psychotic drug (2): weak extrapyramidal side effects. Jpn J Pharmacol 1995; 67 Suppl. I: 144

    Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Aripiprazole. Drugs R&D 2, 47–48 (1999). https://doi.org/10.2165/00126839-199902010-00013

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-199902010-00013

Keywords

Search

Navigation